<DOC>
	<DOCNO>NCT00215514</DOCNO>
	<brief_summary>The main purpose trial determine well patient gastric gastroesophageal junction adenocarcinoma respond chemotherapy epirubicin , cisplatin 5-fluorouracil follow continuous infusion 5-fluorouracil chemotherapy give along radiation therapy .</brief_summary>
	<brief_title>Adjuvant Chemoradiation Therapy Gastric Gastroesophageal Junction Adenocarcinoma</brief_title>
	<detailed_description>- Patients receive epirubicin cisplatin intravenously day 1 treatment . 5-fluorouracil give continuously intravenous infusion bia portable ambulatory pump ( CADD pump ) 21 day . This cycle chemotherapy take 21 day ( 3 week ) . Once complete one week without therapy . - Once patient recover side-effects chemotherapy start combination chemoradiation therapy , 5-fluorouracil radiation . The radiation direct upper abdomen area stomach tumor locate . The radiation therapy give five day week total five week . During five week patient receive 5-fluorouracil continuously CADD pump . - After completion combination chemoradiation therapy three four week rest period follow 2 additional chemotherapy cycle identical first chemotherapy cycle . - The following test procedure perform : physical examination every 4 week except chemoradiation therapy do weekly ; blood test every week chemotherapy chemoradiation ; CT scan chest x-rays do therapy , end therapy , yearly 2 year ; noninvasive test evaluate kidney function start study . - The program chemotherapy radiation therapy last approximately 30 week . After treatment complete , patient return physical examination blood test every 3 month 3 year ; every 6 month 2 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Patients must adenocarcinoma stomach gastroesophageal junction . Adenocarcinomas esophagus involve gastroesophageal junction eligible . Patients must en bloc resection know tumor high risk later failure . The surgical resection must do curative intent . The stomach , lver , peritoneum , omentum regional lymph node must evaluate identified tumor resect . The surgical specimen , pathologic analysis thereof , must adequate TNM stag . Treatment must begin day 20 day 56 gastrectomy . ECOG performance status 0,1 2 ANC &gt; 1,500/ul platelet count &gt; 100,000/ul Serum creatinine &lt; 1.5mg/dl Total bilirubin &lt; 2.0 mg/dl AST &lt; 3 x ULN Estimated caloric intake 1500K calorie per day great Known unresected cancer , microscopic evidence tumor line resection , noncontiguous resection tumor , M1 disease Ascites , peritoneal seeding , liver metastasis extraabdominal metastasis Prior malignancy except adequately treat basal cell squamous cell skin cancer , noninvasive carcinoma situ fully resect , cancer patient disease free five year Previous chemotherapy radiotherapy Active infectious process Pregnant lactate woman Myocardial infarction past 6 month prior history congestive heart failure significant valvular heart disease Uncontrolled serious medical psychiatric condition Grade 2 great peripheral neuropathy baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>adjuvant chemoradiation</keyword>
	<keyword>GE junction</keyword>
	<keyword>epirubicin</keyword>
</DOC>